The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.

Related News Articles

Perspective
On Tuesday, the Census Bureau reported that “a third of Americans now show signs of clinical anxiety or depression” due to the COVID-19 pandemic. It’s also…
Headline
An annual report into death by several factors tied to mental health and wellbeing — otherwise referred to as “deaths of despair” — topped 150,000 in 2018. The…
Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
As part of Mental Health Awareness Month, Bruce Bailey, president and CEO of Tidelands Health based in Georgetown, S.C., talks about how hospitals and health…
Blog
Like all of America’s hospitals, Tidelands Health has a longstanding commitment to improving access to high-quality, affordable services. This includes…
Headline
As we mark Mental Health Awareness Month during the COVID-19 pandemic, it’s important to remember that around 45% of U.S. hospitals and health systems do not…